Oyster Point Pharma prices $80-millon IPO

Oyster Point Pharma (NASDAQ:OYST) priced an initial public offering of five million common shares at a price of $16 each to raise gross proceeds of $80-million. The offering is expected to close on Nov. 4.

The company has given underwriters a 30-day option to purchase up to 750,000 additional shares at the IPO price. J.P. Morgan Securities, Cowen and Co., and Piper Jaffray are acting as joint book-running managers for the offering.

Oyster Point’s lead product candidate, OC-01 is being developed as a nasal spray to treat the signs and symptoms of dry eye disease, a chronic and progressive condition that impacts more than 30 million Americans and is growing in prevalence. 

OC-01’s mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.